Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

New China Life (1336 HK) - Still at a 25% discount to A-shares. Take the deal

New China Life – VONB Is a True Challenge

New China Life Placement - Picked the Bottom for Buying, Hopefully Not the Top for Selling

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

New China Life Insurance / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/swiss-re-ag-1f83dcbc-730e-46fa-82f2-bfe7e8e361a1" target="_blank" data-smartkarma-citation="entities:27914:1" rel="noopener">Swiss Re AG (SREN SW)</a> plans to raise around US$290m via selling all of its remaining stake in <a href="https://www.smartkarma.com/entities/new-china-life-insurance-c-h" target="_blank" data-smartkarma-citation="entities:377:1" rel="noopener">New China Life Insurance (1336 HK)</a>. This is not the first selldown by the company. It last sold a similar sized stake in Oct 2017, which we covered in our note, <a href="https://www.smartkarma.com/insights/new-china-life-placement-picked-the-bottom-for-buying-hopefully-not-the-top-for-selling" target="_blank" rel="noopener">New China Life Placement - Picked the Bottom for Buying, Hopefully Not the Top for Selling</a>.That deal ended up doing well.

Swiss Re AG (SREN SW) plans to raise around US$290m via selling all of its remaining stake in New China Life Insurance (1336 HK). This is not the first selldown by the company. It last sold a similar sized stake in Oct 2017, which we covered in our note, New China Life Placement - Picked the Bottom for Buying, Hopefully Not the Top for Selling.That deal ended up doing well.

New China Life Placement - Clean-Up Helps, past Deal Did Well